News & Publications

Adelaide-based company TekCyte is now seeking investors to fund the expansion of their revolutionary medtech BIOINVISIBLE – a drug-free medical device coating that could curb global rates of infection from implanted devices and potentially save thousands of lives each year. Developed for commercialisation out of the Cell Therapy Manufacturing Cooperative Research Centre, based at the […]

TekCyte’s next-generation medical device coating technology is helping to create safer and better outcomes for patients. It is anti-thrombogenic, anti-proliferative and evidence also now demonstrates extreme reduction in biofilm. The BIOINVISIBLE™ globally patented coating technology is an ultra-thin, highly hydrophilic hyperbranched polyglycerol (HPG) polymer that can be chemically bonded to, for example, a stent or […]

The field of biomedical science and technology has been actively working on improving vascular stents to solve problems relating to the body’s reaction to their presence. Advances in nanotechnology are leading to improved vascular stent coating materials, in some cases making the implantable medical device seem invisible to the body. This is helping vascular surgeons […]

Advances in biomedical equipment, systems and materials are opening new opportunities to create custom made biomedical coatings for the medical industry that have previously been unavailable or too expensive to consider developing for commercial applications. Medical Device Product Development “Our combined biological and biomaterials expertise means we can design ultra-thin, scalable coatings tailored to specific […]

A non-pharmacological approach to reducing device-triggered thrombosis and restenosis Synthetic materials are commonly rejected from the body’s natural defence mechanism. However, there is untapped potential to develop synthetic materials with the innate ability to avoid the body’s natural defence mechanisms from activating. While current materials used in devices has an acceptable level of biocompatibility, there […]

By Dr Tony Simula, PhD MBA BSc(Hons), CEO at TekCyte Peripheral arterial disease (PAD) is characterized by reduced blood flow in the arteries of the lower extremities, due to atherosclerotic occlusive disease. With over 200 million people now affected by the disease worldwide, it is the third leading cause of atherosclerotic vascular morbidity following stroke […]

Every invention takes a team to bring it to market. It requires research and development, with a strong team carrying it through to the stage of commercialisation. The story behind BIOINVISIBLE™ is no different. With highly skilled researchers from a number of different scientific disciplines, a project team was created to work together to improve […]